Larotrectinib: First Global Approval-Reference-Cited by-同舟云学术

Larotrectinib: First Global Approval

Published:2019-01-11 Issue:2 Volume:79 Page:201-206
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Scott Lesley J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-018-1044-x/fulltext.html

Reference16 articles.

1. Berger S, Martens UM, Bochum S. Larotrectinib (LOXO-101). Recent Results Cancer Res. 2018;211:141–51.

2. Vaishnavi A, Le A, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.

3. Kummar S, Lassen UN. TRK inhibition: a new tumor-agnostic treatment strategy. Target Oncol. 2018;13(5):545–56.

4. Loxo Oncology. Vitrakvi® (Larotrectinib): US prescribing information. 2018. https://www.fda.gov/ . Accessed 04 Dec 2018.

5. FDA. FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor [media release]. 2018. https://www.fda.gov/ . Accessed 2018.

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib;Acta Pharmaceutica Sinica B;2024-02

2. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis;Frontiers in Pharmacology;2024-01-31

3. Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-01-09

4. Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules;RSC Medicinal Chemistry;2024

5. Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials;JCO Precision Oncology;2024-01